The U.S. five-year survival rate for lung cancer has increased from 18.1% in 2018 to 31%, according to the American Lung Association’s 2026 “State of Lung Cancer” report published Nov. 16.
Despite nationwide improvement, lung cancer is still the leading cause of cancer deaths in the U.S., and survival rates were considerably lower across states and among certain racial and ethnic groups.
“We must continue to drive progress on lung cancer screening, comprehensive biomarker testing, clinical trials and effective treatments to help people live longer, fuller lives after a lung cancer diagnosis,” Harold Wimmer, president and CEO of the American Lung Association, said in a Nov. 16 news release from the American Lung Association.
For the report, researchers analyzed data from the North American Association of Central Cancer Registries, including its CiNA Explorer tool; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program; and the CDC’s National Program of Cancer Registries and WONDER U.S. Cancer Statistics database.
Here are 9 things to know from the report:
- The lung cancer incidence rate fell 11% between 2018 and 2023. Between 2019 and 2023, incidence ranged from 24.6 per 100,000 people in Utah to 83.9 per 100,000 in Kentucky.
The American Lung Association noted that its incidence data includes 2020, when pandemic-era care disruptions reduced lung cancer diagnoses in a way that may not reflect actual incidence.
- Between 2019 and 2023, 29.3% of lung cancer cases were diagnosed at stage 1, before the cancer had spread, while 42.6% were diagnosed at stage 4.
Patients diagnosed with stage 1 lung cancer had a five-year survival rate of 65%, compared with 12% for those diagnosed at stage 4.
- Only 24.4% of adults at a high risk of developing lung cancer were screened in 2024, with screening rates ranging from 38.7% in Massachusetts to 13.5% in South Dakota.
- The five-year survival rate for lung cancer was 31% for patients diagnosed between 2016 and 2022. Among states with available data, lung cancer survival ranged from 40.9% in Massachusetts to 23.8% in Alabama.
- Five-year lung cancer survival rates were 35.4% for Asian and Pacific Islander patients, 30.8% for white and Latino patients, 26.1% for Black patients and 18.2% for American Indian and Alaska Native patients.
- Compared with white lung cancer patients:
- American Indian and Alaska Native patients were 41% less likely to survive five years, 27% less likely to have surgery and 21% more likely to receive no treatment.
- Black patients were 13% less likely to be diagnosed at an early stage and 17% less likely to have surgery.
- Latino patients and Asian and Pacific Islander patients were both 18% less likely to be diagnosed at an early stage.
- As of August 2025, 19 states required health insurance coverage of comprehensive biomarker testing, which helps determine whether lung cancer patients are candidates for targeted therapy or immunotherapy. Seven states required partial biomarker testing coverage, while 25 states and Washington, D.C., did not require coverage.
- The American Lung Association is urging Congress to pass the Clinical Trial Modernization Act to improve clinical trial access.
- Alongside the report, the American Lung Association released state-level data that allows users to filter lung cancer incidence, five-year survival, early diagnosis, treatment and screening rates, and risk factors.
Read the full report here.